In Brief
The synaptic protein a-synuclein has been strongly implicated in neurodegeneration in Parkinson's disease and related disorders. Using a new Drosophila a-synucleinopathy model, Ordonez et al. show that a-synuclein interacts with spectrin to destabilize the actin cytoskeleton and induce mitochondrial dysfunction.
INTRODUCTION
Parkinson's disease, first formally described 200 years ago by James Parkinson (Parkinson, 1817) , is the second most common neurodegenerative disorder, after Alzheimer's disease, and affects 1 in 50 people over the age of 60 (Franco-Iborra et al., 2016) . The well-described neuropathological hallmarks of Parkinson's disease are loss of nigrostriatal dopaminergic neurons and the formation of a-synuclein rich inclusions known as Lewy bodies (Goedert, 2001) . We now know that Parkinson's disease is one of a larger group of neurodegenerative disorders characterized by aggregation of a-synuclein into inclusion bodies in affected brain tissue; these disorders are collectively termed a-synucleinopathies and include dementia with Lewy bodies and multiple system atrophy. a-synucleinopathies are quite common, with dementia with Lewy bodies accounting for up to one-third of all dementia in older individuals (Barker et al., 2002; Zaccai et al., 2005) .
Human genetics provides important support for the a-synucleinopathy concept. Most patients with Parkinson's disease and related a-synucleinopathies have apparently sporadic disease, but rare mutations in the gene encoding a-synuclein can cause highly penetrant autosomal dominant Parkinson's disease. Examination of brain tissue from patients with a-synuclein mutations reveals the expected loss of dopaminergic nigral neurons and brainstem Lewy bodies but also more widespread aggregation of a-synuclein in cortical neurons as characteristically seen in dementia with Lewy bodies, and in some cases even in the glial cytoplasmic inclusions that define multiple system atrophy (Poulopoulos et al., 2012) . Importantly, a-synuclein mutations causing familial Parkinson's disease include duplications and triplications of the SNCA gene (Lin and Farrer, 2014; Hernandez et al., 2016) , strongly implicating wild-type a-synuclein in neurotoxicity, and supporting the approach taken here and in prior work of modeling Parkinson's disease and related a-synucleinopathies experimentally by expressing the wild-type human protein (Feany and Bender, 2000; Masliah et al., 2000) .
In addition to duplications and triplications, SNCA point mutations (A30P, A53T, E46K) also cause dominant, familial Parkinson's disease (Lin and Farrer, 2014; Hernandez et al., 2016) . However, the mechanism(s) by which increasing levels of wildtype a-synuclein or expression of mutant forms of a-synuclein promote disease pathogenesis remain incompletely understood despite significant effort (Wong and Krainc, 2017) . The impact of familial Parkinson's disease mutations on the normal function of the protein is also unclear. a-synuclein is a soluble and natively unfolded protein enriched in the presynaptic terminal of neurons. Although a number of studies have suggested that a-synuclein plays a role in regulating synaptic neurotransmitter release (Burré et al., 2010; Bendor et al., 2013) , critical interacting partners, molecular conformations, and detailed mechanisms remain undefined.
The relationship between a-synuclein and other proteins encoded by genes mutated in familial Parkinson's disease has also been an important but unresolved issue in Parkinson's disease research. Recessive mutations in PINK1 and parkin cause early-onset forms of familial Parkinson's disease. From the genetic and cell biological perspectives, the two proteins work in an epistatic pathway to control mitochondrial dynamics, turnover, and function (Shulman et al., 2011) . While pathological alterations in mitochondrial energetics and morphology have been described in Parkinson's disease patients (Schapira et al., 1990; Baloyannis et al., 2006) , and in experimental models of a-synucleinopathies (Martin et al., 2006; Bose and Beal, 2016) , a clear mechanistic connection between a-synuclein and mitochondrial dynamics has not been defined. Here we demonstrate, in an experimentally powerful new widespread Drosophila a-synucleinopathy model, that a-synuclein interacts with spectrin, thereby altering F-actin dynamics, promoting mislocalization of the critical mitochondrial fission protein Drp1, and consequently leading to mitochondrial dysfunction and neuronal death.
RESULTS

a-synuclein Impairs Locomotor Ability and Causes Widespread Neurodegeneration
To explore the mechanisms underlying neurotoxicity in the broad group of a-synucleinopathies, we expanded the scope of our previous in vivo Drosophila model of Parkinson's disease, which showed preferentially degeneration of dopaminergic neurons (Feany and Bender, 2000) . We used a recently described binary expression system, the Q system, which relies on the transcriptional activation by the Neurospora protein QF2 to activate transgene expression (Potter et al., 2010) . When we expressed wildtype human a-synuclein in a panneuronal pattern using the Syb-QF2 driver (Riabinina et al., 2015) , we observed higher levels of a-synuclein expression compared with the conventional GAL4/UAS expression system and widespread, robust neurodegeneration ( Figure 1 ). Although expression of a-synuclein was higher than in our previous, more specific, a-synucleinopathy model (compare a-syn PD and a-syn LBD in Figure 1A ), levels of a-synuclein expression were still moderate, equivalent to that of human brain homogenate ( Figure 1A , Hu). Cortical and neuropil vacuole formation (Figures 1C and 1D, arrows) , loss of neurons ( Figure 1E ) and caspase activation (Figures 1F and 1G, arrows) demonstrated robust neurodegeneration. Correlating with extensive neurodegeneration, we observed loss of locomotor activity (Figures 1B and S1B) , as well as reduced lifespan ( Figure S1C ). To control for nonspecific toxicity of expressing an exogenous protein, we expressed GFP using the same expression system and observed no significant neurotoxicity ( Figures S1D and S1E) .
a-synuclein aggregates, defining feature of a-synucleinopathies, were abundant in a-synuclein transgenic flies and increased with age ( Figures 1H and 1I, arrows) . Ubiquitin immunoreactivity is a consistent feature of human Lewy bodies. We therefore determined whether a-synuclein aggregates were ubiquitinated in our new model. Double labeling for a-synuclein and ubiquitin showed that the majority of a-synuclein aggregates also contained ubiquitin ( Figure S1F , arrows). Dopaminergic neurons are preferentially lost in Parkinson's disease. We thus examined dopaminergic neurons specifically in our new a-synuclein transgenic model. We stained tissue sections with an antibody against tyrosine hydroxylase and assessed dopaminergic neurons in the medulla, a site of strong expression mediated by Syb-QF2. a-synuclein transgenic flies had significant loss of TH-immunoreactive dopaminergic neurons compared to control flies ( Figures S1G and S1H, arrows) . We further determined whether a-synuclein aggregates are present in dopaminergic neurons. We co-labeled TH-immunoreactive dopaminergic neurons with an a-synuclein antibody. Medullary as well as central brain dopaminergic neurons contained a-synuclein aggregates ( Figures S1I and S1J, arrows) . Overall, compared to our previous model (Feany and Bender, 2000) , widespread neurodegeneration, early-onset of locomotor deficits, and the formation of numerous a-synuclein aggregates in our new fly a-synucleinopathy model provide an experimentally facile platform to investigate the mechanisms mediating neurodegeneration induced by a-synuclein.
a-synuclein Modulates Actin Dynamics
In a forward genetic screen using the retinal degeneration phenotype present in our previously described a-synuclein transgenic model (Feany and Bender, 2000; Chen and Feany, 2005; Chen et al., 2009 ), we identified a loss of function mutation in Fhos (Formin homology 2 domain containing ortholog), a FHOD class formin, as a suppressor of a-synuclein neurotoxicity (unpublished data, M.B.F.). Analysis of a well-characterized gene expression reporter (enhancer trap), Fhos AA142 (Lammel et al., 2014) , supports neuronal expression of Fhos in the adult brain ( Figure S3M , arrows). Formins nucleate unbranched actin filaments, and previous work has demonstrated that increased Fhos function promotes actin stress fiber formation (Lammel et al., 2014) . We therefore determined whether changes in the actin cytoskeleton accompanied neurodegeneration in our a-synuclein transgenic flies. We first stained whole-mount brains with fluorescently (Alexa Fluor 532) labeled phalloidin, which specifically stains F-actin, and found a substantial increase in a-synuclein transgenic fly brains compared to controls by 10 days of age (Figures 2A and 2B) , although a more modest increase was visible at 1 day of age (Figures S2A and S2B) . To monitor F-actin accumulation biochemically, fly head homogenates were prepared in F-actin stabilizing buffer, pelleted by ultracentrifugation, and F-actin levels determined via immunoblotting. Compared to controls, a-synuclein transgenic flies showed increased F-actin levels ( Figure 2C ). To confirm and quantify our results, we used a sensitive F-actin ELISA (Frenzel et al., 2006) , which demonstrated that the F-actin concentration in homogenates of a-synuclein transgenic fly heads was significantly higher than in that of control flies ( Figure 2D ). Finally, we immunostained brain sections with an antibody that recognizes actin and observed frequent rod-shaped actin-rich inclusions, which increased in number from day 1 to day 10 of age (Figures 2E, arrows, 2F, and S2C) . We have previously demonstrated a correlation between abnormal stabilization of the actin cytoskeleton and actin rod formation . Transgenic mice expressing the Parkinson's disease-linked A53T mutant form of human a-synuclein under the control of the mouse prion protein promoter develop progressive motor abnormalities and neurodegeneration with accompanying a-synuclein aggregation . We assessed these a-synuclein transgenic mice for evidence of actin cytoskeletal abnormalities. When we immunostained sagittal mouse brain sections with an antibody to actin, we observed multiple rodshaped actin inclusions in the brainstem, an area of significant pathology in A53T transgenic mice ( Figures 2G and 2H, arrows) .
Colocalization of MAP2 with actin in mutant mice confirmed the presence of actin rods in neurons (Figures 2J and 2K, arrows) . We also examined transgenic mice expressing moderate levels of wild-type human a-synuclein. These mice do not develop significant neurological or neuropathological abnormalities , and, accordingly, we did not observe actin-rich rods in these asymptomatic animals.
We next examined sections from the cingulate cortex of patients with diffuse neocortical involvement by Lewy body pathology (McKeith et al., 2005) . Similar to results in fly and mouse brains, actin immunostaining revealed rod-shaped, actin-rich inclusions in a-synucleinopathy patients ( Figure 2L , arrows), but not in age-and sex-matched controls who had no evidence of a-synucleinopathy clinically or pathologically. We obtained a fresh sample of cingulate cortex at autopsy of a patient with dementia with Lewy bodies and diffuse neocortical Lewy body pathology, fixed the tissue in paraformaldehyde, stained vibratome sections with fluorescent phalloidin, and were able to confirm that rods from human patients bound phalloidin ( Figure 2M , arrows). 3D reconstruction of phalloidin-stained sections highlighted the rod-shaped morphology of the actin-rich inclusions ( Figure 2M , right). Mouse ( Figure 2I , arrow) and human ( Figures 2N and 2O , arrow) actin rods also contained cofilin, as assessed by double label immunofluorescence. All together, we demonstrate parallel actin cytoskeletal abnormalities in brains of a-synuclein transgenic flies, mice, and a-synucleinopathy patients.
Genetic Manipulation of the Actin Cytoskeleton Rescues a-synuclein-Induced Neurotoxicity To assess the functional significance of actin cytoskeletal alterations in a-synucleinopathy, we performed a series of genetic experiments. We focused on Fhos because we recovered Fhos as a loss-of-function suppressor in our forward genetic screen and on actin directly. We have previously demonstrated that manipulating the levels of Actin5C (Act5C), a nervous system enriched cytoplasmic actin isoform (Wagner et al., 2002) , using the Act5C G0010 loss-of-function mutation can rescue neuronal toxicity associated with excess F-actin stabilization mediated by the microtubule-associated protein tau Figure S3N ), and vacuole formation ( Figures S3C and S3H ) in a-synuclein transgenic flies. Conversely, increasing levels of actin with a UAS-Act5C-GFP transgene worsened climbing ability ( Figures 3A and S3B ), neuronal loss ( Figures 3B and 3C ), and vacuole formation (Figure S3C) . Additionally, coexpressing a-synuclein with an EGFP transgene (UAS-EGFP) had no effect on a-synuclein-induced neurotoxicity ( Figure S3A) , showing the specificity of enhancement by overexpression of Act5C. Modulation of Act5C and Fhos did not affect a-synuclein neurotoxicity simply by altering a-synuclein expression ( Figures S3D and S3I ) or induce toxic effects when expressed in the absence of a-synuclein ( Figures 3C,  S3E , and S3J). Additionally, quantitative real-time PCR revealed that actin-related modifiers had reduced expression of Act5C ( Figure S3F ) and Fhos ( Figure S3K ).
We next determined the effects of actin-related modifiers on the actin cytoskeleton in a-synuclein transgenic flies. Suppressors, including the Act5C loss-of-function mutation and RNAi directed to Fhos normalized F-actin concentrations as determined by ELISA ( Figures 3D and 3J ), while increasing Act5C expression, further increased F-actin levels ( Figure 3D ). Similarly, reducing Act5C levels or Fhos expression decreased the number of actin rods in a-synuclein transgenic flies ( Figures 3E, 3F , 3K, 3L, and S3L), while a further increase in rods was seen in a-synuclein overexpressing Act5C ( Figures 3E, 3F , and S3L). These data support a role for abnormal stabilization of the actin cytoskeleton in mediating a-synuclein neurotoxicity and indicate that the modifiers used exerted their effects by modulating the actin cytoskeleton.
Since genetic modification of the actin cytoskeleton can control both a-synuclein and tau ) neurotoxicity, we determined whether the two neurodegenerative disease-associated proteins interacted in vivo. We began by crossing a-synuclein transgenic flies with flies expressing a mutant human form of tau, tau R406W , found in patients with the familial neurodegenerative disease frontotemporal dementia with parkinsonism linked to chromosome 17. Expression of tau R406W in Drosophila neurons using the panneuronal elav-GAL4 driver creates a level of toxicity amenable to genetic modification and has been widely used as a robust in vivo model of tauopathy (Butzlaff et al., 2015; DuBoff et al., 2012; Frost et al., 2014; Fulga et al., 2007; Khurana et al., 2006; Wittmann et al., 2001) . Remarkably, expressing a-synuclein and tau R406W together was lethal, indicating significant enhancement of a-synuclein by expression of mutant tau. We then crossed a-synuclein transgenic flies with animals expressing wild-type human tau ) in neurons.
Flies expressing a-synuclein and wild-type human tau were recovered and demonstrated enhanced age-related locomotor decline ( Figure S3O ) and neurodegeneration ( Figure S3P ). These findings support a genetic interaction between tau and a-synuclein.
a-synuclein Disrupts Mitochondrial Dynamics via Drp1 Mislocalization
Mitochondrial abnormalities have been implicated in a-synuclein toxicity Lin et al., 2012; Martin et al., 2006) , and we and others have previously described an important role for the F-actin cytoskeleton in controlling mitochondrial dynamics through the key fission protein Drp1 Korobova et al., 2013; Hatch et al., 2014; Moore et al., 2016) . We thus examined mitochondrial morphology in our a-synucleinopathy transgenic flies. Using immunofluorescence 3D reconstruction and electron microscopy, we found that mitochondria were significantly enlarged in the brains of a-synuclein transgenic flies (Figures 4A and 4B, arrows) . Quantification of mitochondrial diameter ( Figure 4C ) and elongation ( Figures 4D and S4A ) confirmed mitochondrial enlargement.
To determine whether abnormalities in mitochondrial morphology correlated with indices of mitochondrial dysfunction, we used the reporter gene MitoTimer (Laker et al., 2014) to assess mitochondrial health in vivo. MitoTimer encodes a mutant form of DsRed protein that fluoresces green when mitochondria are newly synthesized and shifts irreversibly to red fluorescence following oxidation (Laker et al., 2014) . Compared to controls, brains from 10-day-old a-synuclein transgenic flies had a higher red/green fluorescence ratio, indicating increased mitochondrial oxidation (Figures 4E and 4F) , with more modestly increased oxidation present at 1 day of age ( Figure S4B ). To determine whether mitochondrial oxidation correlated with abnormal morphology, we examined red and green fluorescent mitochondria separately for morphological changes and found that enlarged mitochondria are more oxidized ( Figure S4D ). We next stained freshly dissected whole-mount brains with MitoSOX. The MitoSOX dye permeates live cells, where it is targeted to the mitochondria and becomes oxidized by superoxide resulting in strong red fluorescence, which can be detected by microscopy (Robinson et al., 2006) . Fluorescence in the brains of a-synuclein transgenic flies was significantly greater than in control flies (Figures 4G and 4H) , consistent with elevated levels of mitochondrial superoxide. The presence of enlarged mitochondria in our a-synuclein transgenic fly and mouse (Martin et al., 2006) a-synucleinopathy models, prompted us to evaluate the subcellular localization of the key mitochondrial fission protein Drp1. Cytoplasmic Drp1 translocates to the mitochondria to drive fission (Li et al., 2015) . To visualize Drp1, we used a transgenic line that carries an in-frame rescue construct (FLAG-FIAsH-HA-Drp1) expressed under the control of the endogenous Drp1 promoter (Verstreken et al., 2005) . To visualize mitochondria, we used a UAS-Mito-GFP transgene. Drp1 localization to mitochondria was assessed using double label immunofluorescence for HA (Drp1) and GFP (mitochondria). In control flies, Drp1 staining appeared as discrete foci colocalized with mitochondria ( Figure 4I , top panels). However, in a-synuclein transgenic flies, the majority of mitochondria did not show Drp1 colocalization ( Figure 4I , bottom panels), leading to a significant reduction in percent colocalization by quantitative analysis ( Figure 4J ). Super-resolution imaging using structured illumination microscopy and mitochondrial subcellular fractionation confirmed Dpr1 mislocalization (Figures 4K and 4M) . Note that only a small fraction of total Drp1 localizes to mitochondria (Smirnova et al., 2001) , so that the decrease in mitochondrial Drp1 in a-synuclein transgenic flies did not result in a clear increase in cytosolic Drp1 by western blotting of the total cytoplasmic fraction ( Figure 4M ). Compared to control flies, in a-synuclein transgenic flies the fluorescence spectra of Drp1 measured over a 1 mm distance was dissociated from the mitochondrial spectra ( Figure 4L ), and Drp1 levels in the mitochondrial fraction were significantly lower ( Figure 4N ). To ensure that loss of Drp1 localization to mitochondrial protein did not simply reflect reduction in Drp1 protein or changes in mitochondrial biogenesis, we performed immunoblotting experiments that demonstrated equivalent levels of Drp1 (Figures 4M and S5G) and mitochondrial protein ( Figure S4C ) in control and a-synuclein transgenic flies.
To determine whether the mitochondrial dynamics machinery was also altered in vertebrates in response to a-synuclein expression, we examined A53T mutant a-synuclein transgenic mice. Consistent with our previously published results (Martin et al., 2006) , mitochondria had significantly increased size compared to controls ( Figures 4O and 4P ). In comparison, neurologically and neuropathologically normal transgenic mice expressing wild-type human a-synuclein did not show changes in mitochondria morphology ( Figure S4E ).
Drp1 localization to mitochondria in A53T a-synuclein transgenic mice was assessed using double label immunofluorescence for Drp1 and ATPVa (mitochondria). As in flies, human a-synuclein expression in mice resulted in significantly reduced co-immunostaining for Drp1 and mitochondria ( Figure 4O, inset) . Calculation of the Pearson correlation coefficient confirmed a significant reduction in colocalization of mitochondria and Drp1 in A53T a-synuclein mutant mice compared to control littermates ( Figure 4Q ). Similar findings in our fly and mouse a-synucleinopathy models suggest that increased levels of a-synuclein promote mitochondrial enlargement and dysfunction secondary to lack of Drp1 translocation to the mitochondrial outer membrane in a conserved mechanism of neurotoxicity.
Reversing Mitochondrial Abnormalities Rescues a-synuclein-Induced Neurotoxicity To determine whether altered mitochondrial dynamics play a causal role in a-synuclein neurotoxicity, we genetically manipulated mitochondrial dynamics in a-synuclein transgenic flies. We began by assessing the influence of mitochondrial dynamics on a-synuclein toxicity by assaying climbing activity, neuronal loss, and vacuole formation. Overexpression of Drp1 in a-synuclein transgenic flies significantly rescued locomotor deficits ( Figures 5A and S5A ), overall neuronal loss in the medulla (Figures 5B and 5C) , dopaminergic neuronal loss ( Figure S5H ), and vacuole formation ( Figure S5B ). We then determined whether mitochondrial morphological and biochemical abnormalities were also ameliorated in a-synuclein transgenic flies following Drp1 overexpression. We found that increasing expression of Drp1 in a-synuclein transgenic flies normalized mitochondrial size ( Figures 5D and 5E , arrows), decreased mitochondrial oxidation ( Figure 5F ), and reduced mitochondrial superoxide (Figures 5G and 5H) . Using double label immunofluorescence, we confirmed that transgenic expression of Drp1 promoted mitochondrial localization of Drp1 in a-synuclein transgenic flies ( Figure 5I, arrows) . Quantification of the percent localization revealed a significant rescue in colocalization in a-synuclein transgenic flies overexpressing Drp1 ( Figure 5J ). Overexpression of Drp1 using the moderately expressing transgenic line we have previously characterized and used to normalize mitochondrial dynamics in pathological states did not alter a-synuclein levels ( Figure S5C ), locomotor ability ( Figure S5D ), neuronal density ( Figure 5C ), mitochondrial elongation (Figure 5E ), or Drp1 localization (Figures 5J and S5F, arrows) in the absence of transgenic a-synuclein expression. Increased expression of Drp1 mediated by the UAS-Drp1 transgene was confirmed by quantitative real-time PCR ( Figure S5E ). 
Abnormalities in Mitochondria Function Are Downstream of Actin Stabilization
We next took a genetic approach to investigate the relationship between actin cytoskeletal abnormalities and mitochondrial dynamics in a-synuclein transgenic flies. We began by determining whether reversing abnormal F-actin stabilization could rescue mitochondrial abnormalities. When we manipulated the F-actin cytoskeleton by removing one copy of Act5C using the Act5C G0010 allele or by expressing transgenic RNAi directed to
Fhos, we normalized mitochondria morphology ( Figures 6A  and 6D ). Reducing Act5C and Fhos also rescued mitochondrial biochemical abnormalities in a-synuclein transgenic flies as measured by MitoTimer oxidation (Figures 6B and 6E ) and MitoSOX fluorescence ( Figures 6C and 6F ). We then determined whether manipulating actin genetically could influence Drp1 localization. Co-staining for HA-tagged Drp1 and mitochondria (mito-GFP) demonstrated recovery of Drp1 punctate staining ( Figure 6G , arrows) and increased mitochondrial colocalization in a-synuclein transgenic flies with actin-related modifiers (Figures 6H , 6I, and S6A). Additionally, we genetically destabilized actin in a-synuclein transgenic flies and monitored the effects on mitochondrial morphology and Drp1 localization. Overexpression of the actin severing protein Gelsolin (Yin and Stossel, 1979 ) was used to decrease F-actin levels . Increasing levels of Gelsolin (UAS-Gelsolin) reduced mitochondrial elongation ( Figure S6B ) and rescued Drp1 localization ( Figures S6C and  S6D , arrows) in a-synuclein transgenic flies.
a-synuclein Interacts with Spectrin to Disrupt the Actin Cytoskeleton We next addressed the mechanism by which a-synuclein expression altered actin cytoskeletal organization and promoted downstream dysfunction of mitochondria. We focused our attention on spectrins, actin crosslinking proteins that have previously been reported to interact with a-synuclein in vitro and in cell culture Chung et al., 2017) . Spectrins exist primarily as heterotetramers made of a and b subunits. Flies have one a subunit and one conventional b subunit (Dubreuil and Grushko, 1998) , facilitating genetic analysis. We first determine whether modulating a-spectrin levels could influence a-synuclein neurotoxicity. When we increased expression of a-spectrin, motor deficits ( Figures 7A and S7A) , overall neuronal loss ( Figures 7B and S7B) , and dopaminergic neuronal loss ( Figure S7I ) were rescued in a-synuclein transgenic flies. a-synuclein transgenic flies with a-spectrin overexpression also showed reduced F-actin levels ( Figures 7C and S7C ) and decreased numbers of actin rods ( Figures 7D and S7D, arrows) , consistent with an effect of a-spectrin via the actin cytoskeleton. As we would predict given the role of actin in promoting mitochondrial pathology in a-synuclein, we also observed normalization of mitochondrial morphology ( Figures 7E and S7E, arrows) and rescue of Drp1 mislocalization ( Figures 7F and 7G, arrows) with overexpression of a-spectrin. Importantly, overexpression of a-spectrin did not affect a-synuclein expression levels (Figure S7G) or Drp1 localization to the mitochondria in the absence of transgenic a-synuclein expression ( Figure S7F , arrows). We confirmed overexpression of a-spectrin from the UAS-a-spectrin transgene using quantitative real-time PCR ( Figure S7H ).
We also assessed the effects of loss of a-spectrin function on a-synuclein toxicity. Remarkably, expression of human a-synuclein caused lethality in the presence of heterozygosity for each of three loss-of-function mutations, a-spectrin rg41 , a-spectrin lm88 , and a-spectrin MI11816 . In contrast, each of the a-spectrin alleles was viable and healthy as heterozygotes in otherwise wild-type genetic backgrounds, including in the presence of the elav-GAL4 and Syb-QF2 drivers to recapitulate the genetic background of the a-synuclein expression experiment. These findings support a strong genetic interaction between a-synuclein and a-spectrin in vivo.
To investigate the mechanism by which a-spectrin overexpression rescued a-synuclein neurotoxicity in more detail, we immunostained brains from control and a-synuclein transgenic flies with an antibody specific to a-spectrin. Spectrin normally forms a regular subplasmalemmal network that helps maintain the structure and shape of the cell (Machnicka et al., 2012) . 
N). Control in (A)-(D), (G), and (H) is elav-GAL4/+; Syb-QF2. Control in (I)-(L) is elav-GAL4/+; UAS-mito-GFP/+; HA-Drp1/Syb-QF2.
See also Figure S4 . Accordingly, we observed regular staining for a-spectrin at the neuronal cell periphery in control animals. In contrast, the spectrin network was markedly disrupted in a-synuclein transgenic flies ( Figure 7H, arrows) . Disruption of the a-spectrin cytoskeleton was not seen in flies expressing serine 129 phosphorylation incompetent (S129A) a-synuclein but was present with expression of a phosphomimic version (S129D) of a-synuclein (Figure S7L) , consistent with prior work showing preferential binding of spectrin to phosphorylated a-synuclein (McFarland et al., 2008) . Consistent with rescue of neurotoxicity, normal a-spectrin organization was restored with overexpression of a-spectrin in a-synuclein transgenic flies ( Figure 7H, arrows) .
We then performed super-resolution imaging with structured illumination microscopy to investigate the organization of a-synuclein and interacting proteins in more detail. Co-labeling for a-synuclein and a-spectrin revealed close association of the (legend continued on next page) two proteins, as shown in the fluorescence spectral z-profile ( Figures 7I and 7J , arrows). We next assessed the relationship of mitochondria using mito-GFP, F-actin using fluorescent phalloidin, and a-spectrin using a specific antibody. In control flies, we observed that the majority of F-actin colocalized with subplasmalemmal a-spectrin, as expected. In contrast, in a-synuclein transgenic flies, significant amounts of F-actin were relocalized to mitochondria ( Figures 7K and 7L, arrows) . The Pearson correlation coefficient demonstrates the relocalization of F-actin to mitochondria in a-synuclein transgenic animals ( Figure 7M ). We confirmed a close physical interaction between F-actin, a-spectrin, and a-synuclein by precipitating F-actin specifically with biotinylated phalloidin and immunoblotting the resultant precipitate with antibodies against a-spectrin and a-synuclein.
We observed co-precipitation of a-spectrin and a-synuclein with F-actin, confirming our imaging data ( Figures 7N and S7K ).
Since a-spectrin closely associates with a-synuclein ( Figures  7I and 7J ), we wondered whether increasing levels of a-spectrin might alter a-synuclein solubility and thereby modulate neurotoxicity. We thus assessed the number of a-synuclein aggregates using immunofluorescence and the 5G4 a-synuclein monoclonal antibody, which preferentially identifies aggregated forms of a-synuclein (Kovacs et al., 2012) . We observed significantly increased numbers of a-synuclein aggregates and increased size of these aggregates in a-synuclein transgenic flies with a-spectrin overexpression ( Figures 7O and 7P, arrows) . a-synuclein inclusions contained a-spectrin in a-spectrin-overexpressing animals ( Figure S7J , arrows). Changes in a-synuclein solubility were also assessed biochemically. We isolated soluble and insoluble fractions from a-synuclein transgenic fly heads and performed immunoblotting with an antibody specific for a-synuclein. We observed significantly higher a-synuclein levels in the insoluble fraction of a-synuclein flies overexpressing a-spectrin compared to a-synuclein flies ( Figures 7Q and 7R ). These data are consistent with a model in which monomeric or oligomeric a-synuclein binds to and disrupts the spectrin cytoskeleton, disrupting F-actin dynamics and Drp1 localization at mitochondria. Overexpression of a-spectrin promotes aggregation of a-synuclein into larger inclusions that sequester smaller, toxic forms of a-synuclein, restoring F-actin cytoskeletal dynamics and normal mitochondrial function ( Figure S8 ).
DISCUSSION
Despite unequivocal genetic and neuropathological evidence implicating a-synuclein in the pathogenesis of Parkinson's disease and related a-synucleinopathies, the direct molecular targets of a-synuclein and critical downstream mediators of neurodegeneration have remained elusive. Here we couple a new and powerful experimental genetic model of a-synucleinopathy in Drosophila with analyses in mouse and human tissue to outline a molecular cascade of neurotoxicity beginning with direct binding of a-synuclein to a-spectrin, consequent dysregulation of actin dynamics leading to mitochondrial dysfunction and ultimately to cell death ( Figure S8 ). Our identification of spectrin as a target of a-synuclein in vivo (Figure 7) is supported by prior observations of direct or close proximity spectrin interactions with a-synuclein McFarland et al., 2008; Chung et al., 2017) , and more generally by previous implication of the actin cytoskeleton in a-synuclein neurotoxicity (Chung et al., 2009; Gillardon et al., 2008; Khurana et al., 2017; Sousa et al., 2009; Xun et al., 2008) . a-spectrin has also been described as a component of Lewy bodies (Leverenz et al., 2007) , the characteristic protein aggregate of Parkinson's disease and related a-synucleinopathies. Further, a genome-wide association study linked b-spectrin (SPTBN1) to neocortical Lewy body type pathology (Peuralinna et al., 2015) , consistent with a causative link between spectrin and the degree of a-synuclein aggregation into inclusion bodies. Our observation that increasing levels of a-spectrin promotes a-synuclein inclusion formation (Figures 7P and 7R) fits well with these human genetic results.
Intriguingly, binding of a-synuclein to spectrin appears to be strongly promoted by phosphorylation of a-synuclein at serine 129 (McFarland et al., 2008) , a major disease-associated phosphoepitope (Fujiwara et al., 2002) . We have previously demonstrated an important role of phosphorylation of serine 129 in promoting neurotoxicity of a-synuclein and regulating aggregation of the protein in vivo (Chen and Feany, 2005) . In these studies, we found that formation of large inclusions was correlated with protection from a-synuclein toxicity, consistent with our current observations ( Figures 7P and 7R) , and the more general implication of smaller, prefibillar toxic species in a wide range of neurodegenerative diseases characterized by abnormal protein aggregation (Karpinar et al., 2009) .
Our prior studies on aggregation and neurotoxicity of a-synuclein in Drosophila were conducted in previously described transgenic lines with more modest levels of human a-synuclein expression ( Figure 1A ) (Feany and Bender, 2000; Chen and Feany, 2005; Chen et al., 2009 ). These transgenic flies had significant aggregation of a-synuclein, but neurotoxicity was confined to dopaminergic neurons in the brain. In contrast, our current model shows not only widespread aggregation of a-synuclein ( Figure 1H ), but also marked loss of both dopaminergic and nondopaminergic neurons ( Figures 1C-1F and S1G-S1J) and significantly earlier locomotor dysfunction ( Figure 1B) . Our current model also shows a modest reduction in lifespan ( Figure S1C) , which was not a consistent feature of our previous a-synucleinopathy model. Thus, we can now expand our previous model to more accurately represent the wider group of neurodegenerative diseases, including dementia with Lewy bodies, associated with See also Figure S6 .
a-synuclein aggregation and inclusion formation. Of note, clinical neurologists and neuropathologists have increasingly recognized that even in typical Parkinson's disease the earliest (Braak et al., 2003) and some of the most devastating clinical manifestations (Shulman et al., 2011) represent the toxicity of a-synuclein to nondopaminergic neuronal populations. The importance of nonmotor symptoms throughout the course of Parkinson's disease is so significant that these nondopaminergic-derived clinical deficits are now recognized as an important unmet need in Parkinson's disease (Martinez-Martin et al., 2011) . From a practical perspective, the earlier onset and more severe behavioral and neuropathological features of the new model we describe here will enhance the ability to use powerful genetic approaches, and in particularly genome-scale unbiased forward genetics to provide a detailed and comprehensive analysis of the mechanisms controlling a-synuclein neurotoxicity. Although our prior a-synuclein transgenic model had more modest pathology than the new model we now describe (Figure 1) , we were able to perform forward genetic screen based on the retinal degeneration phenotype (Feany and Bender, 2000) , which identified mutations in Fhos as loss-of-function suppressors of a-synuclein neurotoxicity. These findings prompted us to explore the role of the actin cytoskeleton in mediating a-synuclein toxicity in the current study. Our investigations reveal a robust and previously unexpected dysregulation of the actin cytoskeleton in our Drosophila model, in brain tissue from A53T a-synuclein transgenic mice, and in patients with dementia with Lewy bodies as well (Figure 2 ). Abnormal stabilization of the actin cytoskeleton in a-synuclein transgenic flies leads to mislocalization of the key mitochondrial fission protein Drp1 and consequent mitochondrial dysfunction in a pathway that we and other investigators (Hatch et al., 2014; Moore et al., 2016) have investigated in detail. In particular, recent studies suggest a critical role for actin dynamics at the mitochondria to target oligomeric Drp1 to fission sites (Ji et al., 2015) , consistent with excess stabilization of the actin cytoskeleton in a-synuclein transgenic animals (Figures 2 and 7) , including at the mitochondrial membrane (Figures 7K-7M) .
Our findings of mitochondria as important downstream targets of a-synuclein neurotoxicity correlate well with observations of abnormal mitochondrial morphology in Parkinson's disease patients (Baloyannis et al., 2006) , long-standing implication of mitochondrial dysfunction in sporadic Parkinson's disease (Schapira et al., 1990; Bose and Beal, 2016) , and prior association of mitochondrial abnormalities in experimental a-synucleinopathies (Choubey et al., 2011; Menges et al., 2017; Nakamura et al., 2011; O'Donnell et al., 2014) . In addition, our results suggest intriguing commonalities with autosomal recessive forms of familial Parkinson's disease caused by mutations in PINK1 and parkin. These two proteins work in a closely connected pathway to promote normal mitochondrial dynamics and mitophagy (Shulman et al., 2011) . Perhaps even more intriguingly, our mechanistic (Figures 2 and 4) and neurotoxicity ( Figures S3O  and S3P ) findings suggest a possible mechanistic link to the most common group of neurodegenerative diseases, the tauopathies. Tauopathies, including Alzheimer's disease, are characterized by the aggregation and deposition of the microtubule binding protein tau in brains from affected patients. We have previously demonstrated that tau binds actin directly , stabilizing the actin cytoskeleton and perturbing mitochondrial dynamics . Characterization of a similar pathway that controls a-synuclein neurotoxicity is notable given long-standing recognition of clinical and pathological similarities among a-synucleinopathies and tauopathies. The more recent recovery of the TAU locus in genome-wide association studies in Parkinson's disease (Shulman et al., 2011) , and observations that a subset of patients with Parkinson's disease due to mutations in LRRK2 have tauopathy pathology on neuropathological examination (Poulopoulos et al., 2012) , further emphasizes the connections among the disorders and supports the possibility of a common mechanism of pathogenesis as outlined here. Our definition of a new pathway mediating neurotoxicity in a-synucleinopathy suggests potential new therapeutic targets for a-synucleinopathies, which may be applicable to a wide range of common human neurodegenerative disorders, including Alzheimer's disease.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: UAS-a-Spectrin, Ronald Dubreuil; UAS-Mito-GFP, Thomas Schwarz; Fhos-lacZ, Sven Bogdan. UAS-Drp1, UAS-Gelsolin, UAS-S129D, UAS-S129A and human wild-type tau and tau R406W transgenic flies have been described previously Chen and Feany, 2005; Wittmann et al., 2001 ) and currently available upon request.
Mouse and human tissue a-synuclein transgenic mice carrying the familial Parkinson's disease-associated A53T missense mutation (also called G2-3 line or Hualpha-Syn(A53T) were aged until symptomatic (11-14 months old). Asymptomatic human wild-type a-synuclein transgenic mice were used for all experiments at 12 months of age. Controls were littermates not carrying the human wild-type a-synuclein or A53T a-synuclein mutation. Male and female mice were used in all experiments. A total of four animals per genotype were used in each experiment. At the prescribed time point, mouse tissues were fixed in 4% paraformaldehyde and embedded in paraffin. Sections were cut at 7 mm for histological analysis. All experimental protocols involving mice were in strict adherence to the NIH Animal Care and Guidelines and were approved by the Institutional Animal Care and Use Committee at the University of Minnesota. Postmortem human control and a-synucleinopathy brains were collected through the autopsy service at Brigham and Women's Hospital under the appropriate IRB. Control brains included one female and five males with no significant Lewy pathology, Braak stage I/II, a median age of 68.5 and an age range of 57-84 years. a-synucleinopathy brains were from one female and five males with diffuse neocortical Lewy pathology (McKeith et al., 2005) , Braak stage I/II, with a median age of 85 and an age range of 71-94 years. Sections were cut at 6 mm for histological analysis.
METHOD DETAILS
Behavioral and lifespan analysis For climbing assay, ten flies were placed in individual vials for a total of six vials. Flies were lightly tapped down to the bottom of the vial, and the number of flies climbing above 5 cm, within 10 s was recorded. A total of 60 flies of each genotype were used for the assay. Each climbing assay was repeated three times and the mean and standard error of the mean calculated. All flies were maintained at 25 C for the duration of the behavioral assay. For lifespan analysis, 30 flies were aged per vial with a total of 300 flies per genotype. Flies were transferred to fresh food every third day. Aging was performed at 25 C. Mortality was plotted using Kaplan-Meyer analysis in GraphPad Prism 7 software. Tissue processing was carried out as follows: adult flies were fixed in formalin and embedded in paraffin for sectioning. Serial frontal sections (4 mm) of the entire brain were taken and mounted on slides. Mouse brains were fixed in 4% paraformaldehyde and embedded in paraffin for sectioning. Sagittal sections (7 mm) of paraffin-embedded material were prepared for fluorescent labeling. For antigen retrieval slides were microwaved in sodium citrate buffer for 15 min. Immunostaining was performed using secondary antibodies coupled to Alexa Fluor 488 or Alexa Fluor 555. Samples were analyzed on a Zeiss laser-scanning confocal microscope. For brain morphology, sections were stained using hematoxylin and eosin following a standard protocol. The number of vacuoles in the entire medulla was counted. To assay neuronal density, sections were stained with hematoxylin and the number of neurons in an approximately 60 mm 2 area in the anterior medulla was counted. Anterior medulla sections were imaged using the imaging software SPOT and quantitatively analyze using the cell counter plugin in ImageJ.
Immunohistochemistry and histology
Confocal microscopy
Total F-actin levels were determined in adult fly brains as previously described . Briefly, whole brains from adult flies were dissected under a dissection microscope and stained with Alexa Fluor 532 phalloidin (1:1000, Life technologies). Before acquisition, laser parameters were adjusted to obtain nonsaturating conditions. A total of six samples per genotype were processed simultaneously using identical confocal acquisition parameters (laserpower, gain and pinhole settings) on a Zeiss laser-scanning confocal microscope. For quantification of fluorescent staining, average pixel intensity from two-dimensional projections of confocal z stacks were measured using imageJ. Following immunofluorescent staining with an actin antibody, the number of actin-rich rods was determined by counting all rodshaped structures that positively stained for actin in 4 mm frontal brain sections of the entire medulla from flies grown and aged at 25 C. A total of six flies were analyzed per genotype. Actin rod analysis in mice was carried out in the brainstem under the same conditions, in a total of four samples per genotype. For phalloidin staining of human tissue, the cingulate cortex was fixed in 4% paraformaldehyde and sectioned on a vibratome at 30 mm. Sections were then incubated in Alexa Fluor 532 phalloidin for 2 hr and washed with PBS-Triton before mounting. Imaging acquisition was done in a Zeiss laser scanning microscope.
To assess mitochondrial morphology, Kenyon neurons and murine brainstem motor neurons were imaged by confocal microscopy. Mitochondria length and elongation were determined as previously described Dagda et al., 2009) . Briefly, in two-dimensional projections of confocal z stacks, individual mitochondrion diameter was measured by freehand line length in ImageJ. Similarly, mitochondria elongation was determine using the Mito-Morphology micro designed by Ruben K. Dagda at the University of Pittsburg and currently available via ImageJ wiki. A total of 25 mitochondria per sample was used to generate a frequency distribution (diameter) and bar graph (elongation). Mitochondria 3D reconstructions were generated from three-dimensional confocal z stacks using the Imaris software. Reconstruction parameter were used as provided in the software.
Mitochondria and Drp1 colocalization were analyzed using the coloc2 plugin in ImageJ under the same imaging conditions as described above. To assess mitochondria function, superoxide levels and oxidation were measured in adult fly brains using the MitoSOX Red (Invitrogen) dye and the transgene MitoTimer, respectively. Quantification of MitoSOX and MitoTimer fluorescent was performed by averaging the pixel intensity from two-dimensional projections of confocal z stacks using ImageJ. A total of six samples per genotype were used in all actin and mitochondrial analysis.
Electron microscopy
For mitochondrial morphology, brains from 20-day-old a-synuclein and control flies were dissected out of the cuticle and fixed in 2% paraformaldehyde and 2.5% glutaraldehyde (Polysciences). Following incubation in 1% osmium tetroxide (Electron Microscopy Sciences) in 1.5% potassium ferrocyanide (MP Biomedicals) for 1 hr, fly brains were incubated in 1% uranyl acetate for 30 min, and processed through 70, 90 and 100% ethanol solutions. Brains were then incubated in propylene oxide for 1 hr, embedded in Epon/Araldite mixture, and allowed to polymerize for 2 days at 65 C. Thin sections were cut and examined with a conventional Tecnai G 2 Spirit BioTWIN transmission electron microscope.
Structural Illumination Microscopy
To assess mitochondrial, a-synuclein, F-actin, and a-spectrin interactions, 10-day-old fly brains were dissected and fluorescently labeled using standard protocols and mounted using Prolong Diamond antifade mounting medium (Invitrogen). Imaging of Drosophila Kenyon cells was performed using the Zeiss Elyra superresolution microscope. Image deconvolution was carryout using the provided software for the Zeiss Elyra. To assess protein colocalization, we determined the fluorescent spectral of each individual protein across a 1 mm distance in a three-dimensional SIM z stacks using ImageJ.
F-actin isolation and detection
To determine F-actin concentration in a-synuclein transgenic flies, F-actin isolation was performed using the G-actin/F-actin assay (Cytoskeleton). Briefly, ten heads from 10-day-old control and a-synuclein transgenic flies were homogenized in 30 mL of homogenization buffer containing lysis and F-actin stabilization buffer (Cytoskeleton), 1 mM ATP and 1X protease inhibitor cocktail (Thermo Scientific). Homogenates were centrifuged (5 min at 1000 rpm) to pellet debris followed by ultracentrifugation at 37 C (100,000x g) for 1 hr to pellet F-actin. The pellet was solubilized by incubating in F-actin depolymerizing buffer for 1 hr. Soluble F-actin and G-actin fractions were subsequently immunoblotted. The concentrations of primary and secondary antibody were as described below.
Additionally, we used an F-actin ELISA (MyBiosource) to quantitatively assess F-actin levels. One fly brain was homogenized in 30 mL of homogenizing buffer containing F-actin stabilizing buffer (Cytoskeleton), 1 mM ATP, 1X protease inhibitor cocktail (Thermo Scientific) and 1X phosphatase inhibitor (Thermo Scientific). The sample was diluted 1:20 in sample diluent and subsequently transferred into a microplate pre-coated with a F-actin specific antibody. The microplate was then incubated with a biotinylated secondary antibody followed by HRP-avidin. F-actin concentrations were determined using the QuantaBlu fluorogenic peroxidase substrate (Thermo Scientific) as described in the manufacturer's instructions. Each data point is the result of at least three biological replicates each composed of three technical replicates.
Phalloidin Precipitation
To assess a-synuclein, F-actin, and a-spectrin interactions biochemically, F-actin precipitation was performed as previously described in Fulga et al. (2007) . Briefly, 10 fly heads were homogenized in F-actin stabilizing buffer (Cytoskeleton) and centrifuged at 800xg to pellet debris. The supernatant was incubated with 0.3 units biotinylated-phalloidin (Biotin-XX Phalloidin, Life technologies) with rotation for 1 hr at room temperature. Streptavidin-coated magnetic beads (Invitrogen) were blocked for 30 min in homogenization buffer, washed, and resuspended in homogenization buffer. To isolate biotinylated phalloidin-bound protein complexes, streptavidin-coated beads were added to the extracts and incubated for 1 hr at room temperature with rotation. The precipitated material was then washed five times with homogenization buffer, resuspended in SDS loading buffer and subject to immunoblotting. The concentrations of primary and secondary antibody were as described below.
Mitochondrial fractionation
To determine mitochondrial Drp1 levels we performed mitochondria isolation in adult fly heads as previously described . Briefly, 10 fly heads were homogenized in fractionation buffer (250 mM Sucrose, 10 mM Tris-HCl, 1 mM EGTA, pH 7.5) with protease inhibitor cocktail (Thermo Scientific). The homogenate was centrifuged at 800xg to pellet debris, and the supernatant collected and centrifuged at 11,000xg to yield a pellet containing mitochondria and supernatant containing cytoplasmic proteins.
